Those with the MTHFR 677C/C+COMT 158Met/Met genotypes had a significant reduction in percent of subjects meeting endothelial dysfunction criteria (83% at baseline and 16% at endpoint), compared with the MTHFR T/COMT Val allele carriers (54% at baseline and 31% at endpoint; t=−3.57, df=27, P=0.001) as shown in Figure 3. This evidence concerns the gene MTHFR and endothelial dysfunction.